There appears to be some good news for cats who suffer from osteoarthritis.
According to a press release, this month the U.S. Food and Drug Administration approved Solensia, the first treatment for the control of pain associated with osteoarthritis in cats.
Frunevetmab, the active ingredient in Solensia, is a cat-specific monoclonal antibody designed to recognize and attach to a protein called nerve growth factor (NGF) that is involved in the regulation of pain. When frunevetmab binds to NGF, it prevents the pain signal from reaching the brain.
Treatment options for cats with osteoarthritis are very limited, according to the release. Osteoarthritis is a degenerative condition of the joints. Normal cartilage cushion in the joints breaks down and, eventually, the bones in the joint rub against each other, causing pain, decreased joint movement. Sometimes, there is also formation of bone spurs or other changes in and around the joint.
Solensia can help to improve the cat’s quality of life for cats with this condition. The treatment is available only by prescription from a licensed veterinarian and is given through subcutaneous (under the skin) injection once a month.
For more information, about Solensia, visit: https://www.fda.gov/news-events/press-announcements/fda-approves-novel-treatment-control-pain-cats-osteoarthritis-first-monoclonal-antibody-drug-use-any